|
US7407955B2
(en)
|
2002-08-21 |
2008-08-05 |
Boehringer Ingelheim Pharma Gmbh & Co., Kg |
8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
|
|
WO2005012347A2
(en)
*
|
2003-08-05 |
2005-02-10 |
Novo Nordisk A/S |
Novel insulin derivatives
|
|
US7501426B2
(en)
|
2004-02-18 |
2009-03-10 |
Boehringer Ingelheim International Gmbh |
8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
|
|
DE102004054054A1
(de)
|
2004-11-05 |
2006-05-11 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
|
|
DE102005035891A1
(de)
|
2005-07-30 |
2007-02-08 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
|
|
PT1969004E
(pt)
*
|
2005-12-28 |
2011-11-25 |
Novo Nordisk As |
Composições que compreendem uma insulina acilada e zinco e método para criar tais composições
|
|
ATE482977T1
(de)
|
2006-02-27 |
2010-10-15 |
Novo Nordisk As |
Insulinderivate
|
|
PE20080251A1
(es)
|
2006-05-04 |
2008-04-25 |
Boehringer Ingelheim Int |
Usos de inhibidores de dpp iv
|
|
MX2008014024A
(es)
|
2006-05-04 |
2008-11-14 |
Boehringer Ingelheim Int |
Formas poliformas.
|
|
EP1852108A1
(en)
|
2006-05-04 |
2007-11-07 |
Boehringer Ingelheim Pharma GmbH & Co.KG |
DPP IV inhibitor formulations
|
|
US9034818B2
(en)
|
2007-06-13 |
2015-05-19 |
Novo Nordisk A/S |
Pharmaceutical formulations comprising an insulin derivative
|
|
PE20090938A1
(es)
|
2007-08-16 |
2009-08-08 |
Boehringer Ingelheim Int |
Composicion farmaceutica que comprende un derivado de benceno sustituido con glucopiranosilo
|
|
JP5749155B2
(ja)
|
2008-03-18 |
2015-07-15 |
ノボ・ノルデイスク・エー/エス |
プロテアーゼ安定化アシル化インスリンアナログ
|
|
PE20091730A1
(es)
|
2008-04-03 |
2009-12-10 |
Boehringer Ingelheim Int |
Formulaciones que comprenden un inhibidor de dpp4
|
|
BRPI0916997A2
(pt)
|
2008-08-06 |
2020-12-15 |
Boehringer Ingelheim International Gmbh |
Inibidor de dpp-4 e seu uso
|
|
UY32030A
(es)
|
2008-08-06 |
2010-03-26 |
Boehringer Ingelheim Int |
"tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
|
|
MX2011002558A
(es)
|
2008-09-10 |
2011-04-26 |
Boehringer Ingelheim Int |
Terapia de combinacion para el tratamiento de diabetes y estados relacionados.
|
|
US20200155558A1
(en)
|
2018-11-20 |
2020-05-21 |
Boehringer Ingelheim International Gmbh |
Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
|
|
LT2349324T
(lt)
|
2008-10-17 |
2017-12-27 |
Sanofi-Aventis Deutschland Gmbh |
Insulino ir glp-1 agonisto derinys
|
|
ES2607003T3
(es)
|
2008-10-30 |
2017-03-28 |
Novo Nordisk A/S |
Tratamiento de diabetes mellitus utilizando inyecciones de insulina con una frecuencia de inyección inferior a la diaria
|
|
EP2382216A1
(en)
|
2008-12-23 |
2011-11-02 |
Boehringer Ingelheim International GmbH |
Salt forms of organic compound
|
|
TW201036975A
(en)
|
2009-01-07 |
2010-10-16 |
Boehringer Ingelheim Int |
Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy
|
|
EP2395983B1
(en)
|
2009-02-13 |
2020-04-08 |
Boehringer Ingelheim International GmbH |
Pharmaceutical composition comprisng a sglt2 inhibitor, a dpp-iv inhibitor and optionally a further antidiabetic agent and uses thereof
|
|
JP5832439B2
(ja)
|
2009-11-13 |
2015-12-16 |
サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング |
Glp−1アゴニスト、インスリン及びメチオニンを含む薬学的組成物
|
|
CN102711804B
(zh)
|
2009-11-13 |
2015-09-16 |
赛诺菲-安万特德国有限公司 |
包含glp-1激动剂和甲硫氨酸的药物组合物
|
|
EP3646859A1
(en)
|
2009-11-27 |
2020-05-06 |
Boehringer Ingelheim International GmbH |
Treatment of genotyped diabetic patients with dpp-iv inhibitors such as linagliptin
|
|
AU2011249722B2
(en)
|
2010-05-05 |
2015-09-17 |
Boehringer Ingelheim International Gmbh |
Combination therapy
|
|
AU2014203421B2
(en)
*
|
2010-05-19 |
2016-07-07 |
Sanofi |
Long-acting formulations of insulins
|
|
AU2012216648C1
(en)
*
|
2010-05-19 |
2017-03-16 |
Sanofi |
Long-acting formulations of insulins
|
|
AU2011202239C1
(en)
|
2010-05-19 |
2017-03-16 |
Sanofi |
Long-acting formulations of insulins
|
|
CN106975074A
(zh)
*
|
2010-06-24 |
2017-07-25 |
勃林格殷格翰国际有限公司 |
糖尿病治疗
|
|
CN103179978A
(zh)
|
2010-08-30 |
2013-06-26 |
赛诺菲-安万特德国有限公司 |
Ave0010用于制造供治疗2型糖尿病用的药物的用途
|
|
JP6049625B2
(ja)
|
2010-10-27 |
2016-12-21 |
ノヴォ ノルディスク アー/エス |
様々な注射間隔を用いて施されるインスリン注射を使用する、真性糖尿病の治療
|
|
AR083878A1
(es)
|
2010-11-15 |
2013-03-27 |
Boehringer Ingelheim Int |
Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento
|
|
AR085689A1
(es)
|
2011-03-07 |
2013-10-23 |
Boehringer Ingelheim Int |
Composiciones farmaceuticas de metformina, linagliptina y un inhibidor de sglt-2
|
|
US9821032B2
(en)
|
2011-05-13 |
2017-11-21 |
Sanofi-Aventis Deutschland Gmbh |
Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
|
|
UA113626C2
(xx)
*
|
2011-06-02 |
2017-02-27 |
|
Композиція для лікування діабету, що містить кон'югат інсуліну тривалої дії та кон'югат інсулінотропного пептиду тривалої дії
|
|
PH12014500137A1
(en)
|
2011-07-15 |
2017-08-18 |
Boehringer Ingelheim Int |
Substituted quinazolines, the preparation thereof and the use thereof in pharmaceutical compositions
|
|
FR2984749A1
(fr)
*
|
2011-12-23 |
2013-06-28 |
Adocia |
Solution injectable a ph 7 comprenant au moins une insuline basale dont le pi est compris entre 5,8 et 8,5 en combinaison avec une hormone gastro-intestinale a visee therapeutique
|
|
BR112014002986A2
(pt)
|
2011-08-10 |
2017-06-13 |
Adocia |
composição sob a forma de uma solução injetável, e formulação de dose única
|
|
WO2013030160A1
(en)
|
2011-08-29 |
2013-03-07 |
Sanofi-Aventis Deutschland Gmbh |
Pharmaceutical combination for use in glycemic control in diabetes type 2 patients
|
|
TWI559929B
(en)
*
|
2011-09-01 |
2016-12-01 |
Sanofi Aventis Deutschland |
Pharmaceutical composition for use in the treatment of a neurodegenerative disease
|
|
FR2985429B1
(fr)
*
|
2012-01-09 |
2016-07-29 |
Adocia |
Solution injectable a ph 7 comprenant au moins une insuline basale dont le pi est compris entre 5,8 et 8,5 et un polyaminoacide substitue obtenu par un procede de polymerisation controle
|
|
FR2985428B1
(fr)
*
|
2012-01-09 |
2016-05-27 |
Adocia |
Solution injectable a ph 7 comprenant au moins une insuline basale dont le pi est compris entre 5,8 et 8,5 et un polyaminoacide substitue
|
|
WO2013104861A1
(fr)
|
2012-01-09 |
2013-07-18 |
Adocia |
Solution injectable a ph 7 comprenant au moins une insuline basale dont le pi est compris entre 5,8 et 8,5 et un co-polyaminoacide substitue
|
|
US9555001B2
(en)
|
2012-03-07 |
2017-01-31 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition and uses thereof
|
|
US20130303554A1
(en)
|
2012-05-14 |
2013-11-14 |
Boehringer Ingelheim International Gmbh |
Use of a dpp-4 inhibitor in sirs and/or sepsis
|
|
WO2013171167A1
(en)
|
2012-05-14 |
2013-11-21 |
Boehringer Ingelheim International Gmbh |
A xanthine derivative as dpp -4 inhibitor for use in the treatment of podocytes related disorders and/or nephrotic syndrome
|
|
WO2013174767A1
(en)
|
2012-05-24 |
2013-11-28 |
Boehringer Ingelheim International Gmbh |
A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
|
|
FR3001896B1
(fr)
|
2013-02-12 |
2015-07-03 |
Adocia |
Solution injectable a ph 7 comprenant au moins une insuline basale dont le point isolectrique est compris entre 5,8 et 8,5 et un polymere anionique hydrophobise
|
|
US20150314003A2
(en)
|
2012-08-09 |
2015-11-05 |
Adocia |
Injectable solution at ph 7 comprising at least one basal insulin the isoelectric point of which is between 5.8 and 8.5 and a hydrophobized anionic polymer
|
|
UA116217C2
(uk)
|
2012-10-09 |
2018-02-26 |
Санофі |
Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
|
|
FR3001895B1
(fr)
|
2013-02-12 |
2015-07-03 |
Adocia |
Solution injectable a ph7 comprenant au moins une insuline basale dont le point isoelectrique est compris en 5,8 et 8,5 et un compose anionique porteur de charges carboxylates et de radicaux hydrophobes
|
|
SG10201705097PA
(en)
|
2012-12-21 |
2017-07-28 |
Sanofi Sa |
Functionalized exendin-4 derivatives
|
|
TWI641381B
(zh)
|
2013-02-04 |
2018-11-21 |
法商賽諾菲公司 |
胰島素類似物及/或胰島素衍生物之穩定化醫藥調配物
|
|
SG11201506888VA
(en)
|
2013-04-03 |
2015-09-29 |
Sanofi Sa |
Treatment of diabetes mellitus by long-acting formulations of insulins
|
|
US10137172B2
(en)
|
2013-04-30 |
2018-11-27 |
Novo Nordisk A/S |
Administration regime
|
|
WO2015086728A1
(en)
|
2013-12-13 |
2015-06-18 |
Sanofi |
Exendin-4 peptide analogues as dual glp-1/gip receptor agonists
|
|
EP3080154B1
(en)
|
2013-12-13 |
2018-02-07 |
Sanofi |
Dual glp-1/gip receptor agonists
|
|
TW201609796A
(zh)
|
2013-12-13 |
2016-03-16 |
賽諾菲公司 |
非醯化之艾塞那肽-4(exendin-4)胜肽類似物
|
|
TW201609797A
(zh)
|
2013-12-13 |
2016-03-16 |
賽諾菲公司 |
雙重glp-1/升糖素受體促效劑
|
|
EP3091995B1
(en)
|
2014-01-09 |
2024-03-20 |
Sanofi |
Stabilized pharmaceutical formulations of insulin aspart
|
|
US9895424B2
(en)
|
2014-01-09 |
2018-02-20 |
Sanofi |
Stabilized pharmaceutical formulations of insulin analogues and/or insulin derivatives
|
|
JP6735674B2
(ja)
|
2014-01-09 |
2020-08-05 |
サノフイSanofi |
インスリンアスパルトの安定化された医薬製剤
|
|
PE20161153A1
(es)
|
2014-01-20 |
2016-10-27 |
Hanmi Pharm Ind Co Ltd |
Insulina de accion prolongada y uso de la misma
|
|
AR099569A1
(es)
|
2014-02-28 |
2016-08-03 |
Novo Nordisk As |
Derivados de insulina y los usos médicos de estos
|
|
EP3110449B1
(en)
|
2014-02-28 |
2023-06-28 |
Boehringer Ingelheim International GmbH |
Medical use of a dpp-4 inhibitor
|
|
TW201625669A
(zh)
|
2014-04-07 |
2016-07-16 |
賽諾菲公司 |
衍生自艾塞那肽-4(Exendin-4)之肽類雙重GLP-1/升糖素受體促效劑
|
|
TW201625668A
(zh)
|
2014-04-07 |
2016-07-16 |
賽諾菲公司 |
作為胜肽性雙重glp-1/昇糖素受體激動劑之艾塞那肽-4衍生物
|
|
TW201625670A
(zh)
|
2014-04-07 |
2016-07-16 |
賽諾菲公司 |
衍生自exendin-4之雙重glp-1/升糖素受體促效劑
|
|
AR100639A1
(es)
*
|
2014-05-29 |
2016-10-19 |
Hanmi Pharm Ind Co Ltd |
Composición para tratar diabetes que comprende conjugados de análogos de insulina de acción prolongada y conjugados de péptidos insulinotrópicos de acción prolongada
|
|
TWI684458B
(zh)
|
2014-05-30 |
2020-02-11 |
南韓商韓美藥品股份有限公司 |
包含胰島素及glp-1/昇糖素雙重促效劑之治療糖尿病之組成物
|
|
US9932381B2
(en)
|
2014-06-18 |
2018-04-03 |
Sanofi |
Exendin-4 derivatives as selective glucagon receptor agonists
|
|
MA41138B1
(fr)
|
2014-12-12 |
2023-07-31 |
Sanofi Aventis Deutschland |
Formulation à rapport fixe d'insuline glargine/lixisenatide
|
|
TWI748945B
(zh)
|
2015-03-13 |
2021-12-11 |
德商賽諾菲阿凡提斯德意志有限公司 |
第2型糖尿病病患治療
|
|
TW201705975A
(zh)
|
2015-03-18 |
2017-02-16 |
賽諾菲阿凡提斯德意志有限公司 |
第2型糖尿病病患之治療
|
|
AR105319A1
(es)
|
2015-06-05 |
2017-09-27 |
Sanofi Sa |
Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
|
|
AR105284A1
(es)
|
2015-07-10 |
2017-09-20 |
Sanofi Sa |
Derivados de exendina-4 como agonistas peptídicos duales específicos de los receptores de glp-1 / glucagón
|
|
UY36870A
(es)
|
2015-08-28 |
2017-03-31 |
Hanmi Pharm Ind Co Ltd |
Análogos de insulina novedosos
|
|
CN108431019A
(zh)
|
2015-10-07 |
2018-08-21 |
阿佩利斯制药有限公司 |
给药方案
|
|
WO2017211979A1
(en)
|
2016-06-10 |
2017-12-14 |
Boehringer Ingelheim International Gmbh |
Combinations of linagliptin and metformin
|
|
WO2018055539A1
(en)
*
|
2016-09-22 |
2018-03-29 |
Wockhardt Limited |
Pharmaceutical composition containing buffered insulin glargine and glp-1 analogue
|
|
RU2764197C1
(ru)
|
2016-09-23 |
2022-01-14 |
Ханми Фарм. Ко., Лтд. |
Аналоги инсулина с пониженной аффинностью к рецептору инсулина и их применение
|
|
US20180169190A1
(en)
|
2016-12-16 |
2018-06-21 |
Novo Nordisk A/S |
Insulin containing pharmaceutical compositions
|
|
WO2018174668A2
(ko)
|
2017-03-23 |
2018-09-27 |
한미약품 주식회사 |
인슐린 수용체와의 결합력이 감소된 인슐린 아날로그의 결합체 및 이의 용도
|
|
CN110831544B
(zh)
|
2017-04-07 |
2022-11-18 |
阿佩利斯制药有限公司 |
长效坎普他汀类似物、其组合物的给药方案及其医药用途
|
|
WO2019118938A1
(en)
|
2017-12-15 |
2019-06-20 |
Apellis Pharmaceuticals, Inc. |
Dosing regimens and related compositions and methods
|
|
US10335464B1
(en)
|
2018-06-26 |
2019-07-02 |
Novo Nordisk A/S |
Device for titrating basal insulin
|
|
CN114096269B
(zh)
|
2019-07-12 |
2024-06-11 |
诺和诺德股份有限公司 |
高浓度胰岛素制剂
|
|
CN110669680A
(zh)
*
|
2019-11-04 |
2020-01-10 |
张少清 |
黑酵母菌的培养方法及从黑酵母菌中提取β葡聚糖的工艺
|
|
WO2021105393A1
(en)
|
2019-11-29 |
2021-06-03 |
Novo Nordisk A/S |
Processes for obtaining stable glp-1 compositions
|
|
WO2021142733A1
(en)
*
|
2020-01-16 |
2021-07-22 |
Shanghai Benemae Pharmaceutical Corporation |
Combinational therapy comprising glp-1 and/or glp-1 analogs, and insulin and/or insulin analogs
|
|
EP4090351A4
(en)
*
|
2020-01-16 |
2023-09-13 |
Shanghai Benemae Pharmaceutical Corporation |
Dosing regimen of glp-1
|
|
JP2023538871A
(ja)
*
|
2020-08-12 |
2023-09-12 |
ティーエックスピー ファーマ エージー |
エキセンジン-4ペプチド類似体
|
|
WO2022268208A1
(zh)
*
|
2021-06-25 |
2022-12-29 |
甘李药业股份有限公司 |
含酰化胰岛素的药物组合物
|
|
US20250000948A1
(en)
|
2021-11-15 |
2025-01-02 |
Adocia |
Solid compositions comprising a peptide or a protein and an acylated amino acid
|
|
EP4180060A1
(en)
|
2021-11-15 |
2023-05-17 |
Adocia |
Solid compositions comprising a peptide or a protein and an acylated amino acid
|
|
EP4299057A1
(en)
|
2022-06-30 |
2024-01-03 |
Adocia |
Solid compositions comprising a peptide or a protein and an acylated amino acid
|
|
EP4299071A1
(en)
|
2022-07-01 |
2024-01-03 |
Adocia |
Compositions comprising a peptide or a protein and an acylated amino acid
|